## Thorsten Stiewe

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7245313/thorsten-stiewe-publications-by-year.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114<br/>papers3,930<br/>citations31<br/>h-index61<br/>g-index127<br/>ext. papers6,010<br/>ext. citations9.8<br/>avg, IF5.64<br/>L-index

#	Paper	IF	Citations
114	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. <i>Cancer Research</i> , <b>2022</b> , 82, PD2-04-PD2-04	10.1	
113	Partial p53 reactivation is sufficient to induce cancer regression <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 80	12.8	0
112	The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA <i>HemaSphere</i> , <b>2022</b> , 6, e0708	0.3	
111	Robustness of the Autophagy Pathway to Somatic Copy Number Losses. <i>Cells</i> , <b>2022</b> , 11, 1762	7.9	
110	RNA inhibits dMi-2/CHD4 chromatin binding and nucleosome remodeling. <i>Cell Reports</i> , <b>2022</b> , 39, 11089	9510.6	
109	The multicellular signalling network of ovarian cancer metastases. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e633	5.7	2
108	Modulation of Pancreatic Neuroendocrine Neoplastic Cell Fate by Autophagy-Mediated Death. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 965-985	5.6	7
107	Activation of Cilia-Independent Hedgehog/GLI1 Signaling as a Novel Concept for Neuroblastoma Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
106	Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
105	The SAM domain-containing protein 1 (SAMD1) acts as a repressive chromatin regulator at unmethylated CpG islands. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	3
104	Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer. <i>Theranostics</i> , <b>2021</b> , 11, 1377-1395	12.1	6
103	Ush regulates hemocyte-specific gene expression, fatty acid metabolism and cell cycle progression and cooperates with dNuRD to orchestrate hematopoiesis. <i>PLoS Genetics</i> , <b>2021</b> , 17, e1009318	6	2
102	IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
101	Efficient antisense inhibition reveals microRNA-155 to restrain a late-myeloid inflammatory programme in primary human phagocytes. <i>RNA Biology</i> , <b>2021</b> , 18, 604-618	4.8	1
100	C1q/TNF-Related Protein 3 (CTRP-3) Deficiency of Adipocytes Affects White Adipose Tissue Mass but Not Systemic CTRP-3 Concentrations. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
99	JAZF1, A Novel p400/TIP60/NuA4 Complex Member, Regulates H2A.Z Acetylation at Regulatory Regions. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
98	p53 partial loss-of-function mutations sensitize to chemotherapy Oncogene, 2021,	9.2	5

### (2019-2020)

97	YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
96	LITESEC-T3SS - Light-controlled protein delivery into eukaryotic cells with high spatial and temporal resolution. <i>Nature Communications</i> , <b>2020</b> , 11, 2381	17.4	8
95	Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion. <i>Molecular Oncology</i> , <b>2020</b> , 14, 2142-2162	7.9	7
94	Reprogramming of tumor-associated macrophages by targeting Eatenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , <b>2020</b> , 6, eaaz6105	14.3	35
93	HDAC3 functions as a positive regulator in Notch signal transduction. <i>Nucleic Acids Research</i> , <b>2020</b> , 48, 3496-3512	20.1	9
92	p53ቼ Extended Reach: The Mutant p53 Secretome. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	23
91	Long-term cultivation using ineffective MDM2 inhibitor concentrations alters the drug sensitivity profiles of PL21 leukaemia cells. <i>Experimental Results</i> , <b>2020</b> , 1,	1.3	1
90	Distinct IL-1E esponsive enhancers promote acute and coordinated changes in chromatin topology in a hierarchical manner. <i>EMBO Journal</i> , <b>2020</b> , 39, e101533	13	13
89	Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. <i>Cell Cycle</i> , <b>2020</b> , 19, 109-123	4.7	6
88	Epigenetic Inactivation of the Tumor Suppressor Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
87	The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. <i>Nature</i> , <b>2020</b> , 586, 133-138	50.4	94
86	Metastasis-Associated Protein 2 Represses NF- <b>B</b> to Reduce Lung Tumor Growth and Inflammation. <i>Cancer Research</i> , <b>2020</b> , 80, 4199-4211	10.1	3
85	Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging. <i>Cancer Research</i> , <b>2020</b> , 80, 5231-5244	10.1	9
84	mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. <i>Nature Communications</i> , <b>2020</b> , 11, 4684	17.4	34
83	Extracellular Vesicles: Messengers of p53 in Tumor-Stroma Communication and Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	9
82	Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 11388-	-1 <sup>5</sup> 1 <sup>4</sup> 07	18
81	SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells. <i>Nature Communications</i> , <b>2019</b> , 10, 1335	17.4	511
80	Drosophila melanogaster tPlus3a and tPlus3b ensure full male fertility by regulating transcription of Y-chromosomal, seminal fluid, and heat shock genes. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213177	3.7	1

79	Downregulation of miR-503 in Activated Kidney Fibroblasts Disinhibits KCNN4 in an in Vitro Model of Kidney Fibrosis. <i>Kidney and Blood Pressure Research</i> , <b>2019</b> , 44, 113-122	3.1	5
78	The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. <i>Nature Communications</i> , <b>2019</b> , 10, 760	17.4	129
77	Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF- <b>B</b> p65-Regulated Gene Expression. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
76	Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase Gene as Resistance Factor. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
75	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. <i>Theranostics</i> , <b>2019</b> , 9, 6047-6062	12.1	25
74	Distinct CoREST complexes act in a cell-type-specific manner. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, 11649-1	1 <u>66</u> 61	2
73	Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. <i>EMBO Journal</i> , <b>2019</b> , 38, e102096	13	17
72	Specific allelic variants of SNPs in the and genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. <i>Oncotarget</i> , <b>2019</b> , 10, 1975-1992	3.3	2
71	Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 22288-22293	11.5	9
70	ADAR1 Is Required for Dendritic Cell Subset Homeostasis and Alveolar Macrophage Function. Journal of Immunology, <b>2019</b> , 202, 1099-1111	5.3	5
69	Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. <i>Molecular Oncology</i> , <b>2019</b> , 13, 185-201	7.9	28
68	NF- <b>B</b> p65 dimerization and DNA-binding is important for inflammatory gene expression. <i>FASEB Journal</i> , <b>2019</b> , 33, 4188-4202	0.9	18
67	Combined cistrome and transcriptome analysis of SKI in AML cells identifies SKI as a co-repressor for RUNX1. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 3412-3428	20.1	10
66	Chromatin Binding of -REL and p65 Is Not Limiting for Macrophage Transcription During Immediate Suppression by Ovarian Carcinoma Ascites. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1425	8.4	6
65	Histone variant H2A.Z deposition and acetylation directs the canonical Notch signaling response. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 8197-8215	20.1	25
64	How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. <i>Drug Resistance Updates</i> , <b>2018</b> , 38, 27-43	23.2	58
63	MGA, L3MBTL2 and E2F6 determine genomic binding of the non-canonical Polycomb repressive complex PRC1.6. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007193	6	54
62	The Genes for Tissue Factor F3 and Nuclear Receptor 4A Are Down-Regulated in Early Death Acute Promyelocytic Leukemia Patients. <i>Blood</i> , <b>2018</b> , 132, 3902-3902	2.2	

#### (2015-2018)

61	Miz1 Controls Schwann Cell Proliferation via H3K36 Demethylase Kdm8 to Prevent Peripheral Nerve Demyelination. <i>Journal of Neuroscience</i> , <b>2018</b> , 38, 858-877	6.6	12
60	Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 270-289	7.6	34
59	PWWP2A binds distinct chromatin moieties and interacts with an MTA1-specific core NuRD complex. <i>Nature Communications</i> , <b>2018</b> , 9, 4300	17.4	22
58	Transcription factor Sp2 potentiates binding of the TALE homeoproteins Pbx1:Prep1 and the histone-fold domain protein Nf-y to composite genomic sites. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 19250-19262	5.4	4
57	Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes. <i>Cell Reports</i> , <b>2018</b> , 24, 3339-3352	10.6	18
56	p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding. <i>Molecular and Cellular Oncology</i> , <b>2017</b> , 4, e1288678	1.2	2
55	CK1lablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E8035-E8044	11.5	22
54	Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. <i>BMC Genomics</i> , <b>2017</b> , 18, 243	4.5	27
53	ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. <i>Clinical Epigenetics</i> , <b>2017</b> , 9, 60	7.7	11
52	Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2410	9.8	25
51	A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. <i>Genome Biology</i> , <b>2016</b> , 17, 108	18.3	64
50	Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 3204-18	20.1	15
49	CRISPR-Cas9-based target validation for p53-reactivating model compounds. <i>Nature Chemical Biology</i> , <b>2016</b> , 12, 22-8	11.7	54
48	The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. <i>Oncotarget</i> , <b>2016</b> , 7, 75339-75352	3.3	61
47	Galectin-3 interacts with components of the nuclear ribonucleoprotein complex. <i>BMC Cancer</i> , <b>2016</b> , 16, 502	4.8	26
46	Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E84	4 <del>3</del> 3-€8	34 <del>4</del> 2
45	Altered glycogen metabolism causes hepatomegaly following an Atg7 deletion. <i>Cell and Tissue Research</i> , <b>2016</b> , 366, 651-665	4.2	5
44	Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2690-8	1.9	4

43	A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism. <i>Cancer Cell</i> , <b>2015</b> , 27, 877-878	24.3	2
42	Zinc finger independent genome-wide binding of Sp2 potentiates recruitment of histone-fold protein Nf-y distinguishing it from Sp1 and Sp3. <i>PLoS Genetics</i> , <b>2015</b> , 11, e1005102	6	29
41	The transcriptional PPAR/Inetwork in human macrophages defines a unique agonist-induced activation state. <i>Nucleic Acids Research</i> , <b>2015</b> , 43, 5033-51	20.1	44
40	The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. <i>Molecular Carcinogenesis</i> , <b>2015</b> , 54, 585-97	5	24
39	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139	0 <i>7.<del>3</del></i>	66
38	Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. <i>EMBO Journal</i> , <b>2015</b> , 34, 517-30	13	63
37	Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123181	3.7	6
36	Deregulation of PPAR/Harget genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. <i>Oncotarget</i> , <b>2015</b> , 6, 13416-33	3.3	58
35	Lung tumors on multimodal radiographs derived from grating-based X-ray imaginga feasibility study. <i>Physica Medica</i> , <b>2014</b> , 30, 352-7	2.7	21
34	Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. <i>Nature Communications</i> , <b>2014</b> , 5, 3981	17.4	13
33	A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1689-704	4.9	24
32	A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. <i>Cancer Cell</i> , <b>2013</b> , 24, 242-56	24.3	164
31	p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. <i>Cell Reports</i> , <b>2013</b> , 3, 1512-25	10.6	58
30	Targeting p73 in cancer. Cancer Letters, 2013, 332, 229-36	9.9	27
29	Characterization of the p53 cistromeDNA binding cooperativity dissects p53% tumor suppressor functions. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003726	6	69
28	iTRAQ analysis of a cell culture model for malignant transformation, including comparison with 2D-PAGE and SILAC. <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 2140-53	5.6	24
27	Depletion of the TP53 Family Member p73 Sensitizes Cancer Cells towards Cytarabine <i>Blood</i> , <b>2012</b> , 120, 2461-2461	2.2	
26	Up-Regulation of Heme Oxygenase-1 Is Induced by the Leukemia Stroma-Cell Interaction and Rescues Acute Myeloid Leukaemia (AML) Cells From Cytarabin Induced Cell Death. <i>Blood</i> , <b>2012</b> , 120, 533-533	2.2	

### (2003-2012)

25	Expression of the Nuclear Corepressor Ski Predicts Response to Histone Deacetylase Inhibitor Valproic Acid in Cells of Acute Myeloid Leukemia <i>Blood</i> , <b>2012</b> , 120, 2410-2410	2.2	
24	MicroRNA29a regulates the expression of the nuclear oncogene Ski. <i>Blood</i> , <b>2011</b> , 118, 1899-902	2.2	31
23	Life or death: p53-induced apoptosis requires DNA binding cooperativity. <i>Cell Cycle</i> , <b>2010</b> , 9, 4068-76	4.7	40
22	Malignant transformation in a defined genetic background: proteome changes displayed by 2D-PAGE. <i>Molecular Cancer</i> , <b>2010</b> , 9, 254	42.1	14
21	DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. <i>Molecular Cell</i> , <b>2010</b> , 38, 356-68	17.6	69
20	p53 and p73 in suppression of Myc-driven lymphomagenesis. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 502-6	7.5	6
19	Induction of early growth response-1 mediates microglia activation in vitro but is dispensable in vivo. <i>NeuroMolecular Medicine</i> , <b>2009</b> , 11, 87-96	4.6	13
18	Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. <i>PLoS ONE</i> , <b>2009</b> , 4, e7768	3.7	24
17	miRNA29a Regulates Oncogenic SKI Expression in Acute Myeloid Leukemia (AML) <i>Blood</i> , <b>2009</b> , 114, 1968-1968	2.2	1
16	p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. <i>EMBO Journal</i> , <b>2008</b> , 27, 792-803	13	44
15	KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 862-75	9.7	51
14	C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. <i>Nucleic Acids Research</i> , <b>2008</b> , 36, 1900-12	20.1	45
13	In good times and bad: p73 in cancer. <i>Cell Cycle</i> , <b>2008</b> , 7, 1726-31	4.7	30
12	The p53 family in differentiation and tumorigenesis. <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 165-8	31.3	243
11	p53 family members in myogenic differentiation and rhabdomyosarcoma development. <i>Cancer Cell</i> , <b>2006</b> , 10, 281-93	24.3	97
10	Quantitative TP73 transcript analysis in hepatocellular carcinomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 626-33	12.9	62
9	Mechanism of E2F1-induced apoptosis in primary vascular smooth muscle cells. <i>Cardiovascular Research</i> , <b>2003</b> , 59, 512-9	9.9	13
8	Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 14230-6	5.4	31

7	Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. <i>Molecular Therapy</i> , <b>2002</b> , 5, 405-12	11.7	25
6	Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 14177-85	5.4	140
5	Gene expression changes in response to E2F1 activation. <i>Nucleic Acids Research</i> , <b>2002</b> , 30, 1859-67	20.1	132
4	Transactivation-deficient DeltaTA-p73 acts as an oncogene. <i>Cancer Research</i> , <b>2002</b> , 62, 3598-602	10.1	112
3	Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor. <i>Molecular and Cellular Neurosciences</i> , <b>2001</b> , 18, 68-79	4.8	22
2	Role of the p53-homologue p73 in E2F1-induced apoptosis. <i>Nature Genetics</i> , <b>2000</b> , 26, 464-9	36.3	305

TP53mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance 1